Loading…
Curis, Inc. is projected to decline to $4.96 by 2027, a -4% move from its current price of $5.15. CRIS is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $4.84 | $5.15 | $5.49 | +0.07% |
| Aug 6 | $4.72 | $5.16 | $5.64 | +0.14% |
| Aug 7 | $4.63 | $5.16 | $5.76 | +0.22% |
| Aug 8 | $4.55 | $5.16 | $5.86 | +0.29% |
| Aug 9 | $4.49 | $5.17 | $5.95 | +0.36% |
| Aug 10 | $4.43 | $5.17 | $6.04 | +0.43% |
| Aug 11 | $4.38 | $5.18 | $6.12 | +0.50% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $4.38 | $5.18 | $6.12 | +0.50% |
| Week 2 | $4.11 | $5.20 | $6.59 | +1.01% |
| Week 3 | $3.92 | $5.23 | $6.98 | +1.52% |
| Week 4 | $3.76 | $5.25 | $7.34 | +2.03% |
| Week 5 | $3.64 | $5.28 | $7.67 | +2.55% |
| Week 6 | $3.53 | $5.31 | $7.99 | +3.06% |
| Week 7 | $3.43 | $5.33 | $8.29 | +3.58% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Curis, Inc. is a biotechnology company that engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed/refractory primary central nervous system lymphoma.
The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small-molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3.
It has collaboration agreements with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed three programs under the Aurigene collaboration, including emavusertib.
Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.
Curis, Inc. (CRIS) is currently priced at $4.73 with a market capitalization of $9.22M, and it is ranked 5156 in market listings.
The near-term forecast for 2026 shows an average price of $4.73, a min of $4.20, and a max of $7.28; ROI is 0 and sentiment is NEUTRAL.
The longer-term forecast indicates bullish momentum starting in 2030, with the 2030 average of $6.69 (ROI 41.4) and the 2031 average of $6.58 (ROI 39.1). The 2040 forecast shows an average of $5.91 (ROI 25) and the 2050 forecast shows an average of $16.38 (ROI 246.3), signaling meaningful upside over the longer horizon.
A major floor 95.9% below — a decisive break under it would weaken the trend.
The nearest floor, 18.4% below — buyers have tended to step in here.
The nearest ceiling, 101.9% above — a clean break opens room to run.
A major ceiling 101.9% above — clearing it would confirm fresh momentum.
Key CRIS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CRIS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $4.90 | Buy | $4.93 | Buy |
| MA 10 | $4.83 | Buy | $4.80 | Buy |
| MA 20 | $4.90 | Buy | $4.27 | Buy |
| MA 50 | $2.23 | Buy | $2.91 | Buy |
| MA 100 | $1.43 | Buy | $2.05 | Buy |
| MA 200 | $1.30 | Buy | $1.74 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 68.77 | Neutral |
| Stoch RSI (14) | 24.64 | Neutral |
| CCI (20) | 40.07 | Neutral |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | -0.11 | Sell |
| ROC (12) | 6.13 | Buy |
| Bollinger %B (20,2) | 0.60 | Neutral |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 5.28 | Buy |
| Awesome (5,34) | 1.85 | Buy |
| Ultimate (7,14,28) | 57.10 | Neutral |
| Momentum (10) | 0.39 | Buy |
| Aroon Osc (25) | 24.00 | Buy |
| Hull MA (9) | 5.00 | Buy |
| ADX (14) | 39.26 | Buy |
| ATR (14) | 0.24 | Info |
The 30-day technical picture is BEARISH. RSI14 is 40. SMA50 is $8.72 and SMA200 is $18.24. The 30-day range spans from $2.72 to $8.22, with key support at $4.20 and resistance at $10.40. Annualized volatility is 200%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $4.20 | $5.15 | $7.49 | 0% | Neutral | |
| $3.61 | $4.96 | $7.35 | -4% | Neutral | |
| $3.17 | $4.63 | $7.32 | -10% | Neutral | |
| $3.52 | $5.42 | $9.01 | +5% | Neutral | |
| $4.63 | $7.47 | $12.93 | +45% | Bullish | |
| $4.32 | $7.29 | $13.07 | +42% | Bullish | |
| $3.38 | $5.95 | $11.00 | +15% | Neutral | |
| $3.44 | $6.30 | $11.98 | +22% | Bullish | |
| $3.04 | $5.80 | $11.30 | +13% | Neutral | |
| $3.43 | $6.79 | $13.54 | +32% | Bullish | |
| $2.90 | $6.44 | $14.12 | +25% | Bullish | |
| $7.70 | $17.11 | $39.35 | +232% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $4.20 | $5.15 | $6.20 | +0.00% |
| September 2026 | $4.43 | $5.38 | $6.82 | +4.47% |
| October 2026 | $4.46 | $5.50 | $7.12 | +2.20% |
| November 2026 | $4.28 | $5.34 | $7.02 | -2.89% |
| December 2026 | $4.46 | $5.62 | $7.49 | +5.19% |
Click any year to see its month-by-month CRIS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, CRIS could reach as high as $7.49, with a base case around $5.15 and support toward $4.20 — roughly 0% from $5.15. Price action looks broadly range-bound.
Expect CRIS to range from $3.61 to $7.35 through 2027. The $4.96 average target implies a -4% move from current prices. That is -4% versus the projected 2026 average. A consolidation phase looks the most probable path here.
The CRIS price prediction for 2028 points to an average of $4.63 (low $3.17, high $7.32) — a potential decline of -10% on today's $5.15. Price action looks broadly range-bound.
In 2029, CRIS is projected to trade between $3.52 and $9.01, averaging $5.42 — a potential gain of +5% from today's $5.15. That is up +17% on the projected 2028 average. A consolidation phase looks the most probable path here.
Curis, Inc.'s 2030 outlook centres on $7.47, within a $4.63 to $12.93 range. That is up +38% on the projected 2029 average. That marks a +45% change versus current levels. Momentum favours further upside here.
By 2031, CRIS could reach as high as $13.07, with a base case around $7.29 and support toward $4.32 — roughly +42% from $5.15. Buyers look set to stay in control over this stretch.
Expect CRIS to range from $3.38 to $11.00 through 2032. The $5.95 average target implies a +15% move from current prices. That is -18% versus the projected 2031 average. Price action looks broadly range-bound.
The CRIS price prediction for 2033 points to an average of $6.30 (low $3.44, high $11.98) — a potential gain of +22% on today's $5.15. Buyers look set to stay in control over this stretch.
In 2034, CRIS is projected to trade between $3.04 and $11.30, averaging $5.80 — a potential gain of +13% from today's $5.15. That is -8% versus the projected 2033 average. Price action looks broadly range-bound.
Curis, Inc.'s 2035 outlook centres on $6.79, within a $3.43 to $13.54 range. That is up +17% on the projected 2034 average. That marks a +32% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, CRIS could reach as high as $14.12, with a base case around $6.44 and support toward $2.90 — roughly +25% from $5.15. Momentum favours further upside here.
Expect CRIS to range from $7.70 to $39.35 through 2050. The $17.11 average target implies a +232% move from current prices. That is up +166% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in CRIS today (≈ 194.174757 CRIS) could be worth
$3,321.82
+$2,321.82 (+232%) by 2050 · US Dollar
Based on the average projected CRIS price of $17.11 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CRISwould be worth at today's price.
$1,000 invested in CRIS on Jul 31, 2025 (≈ 602.409651 CRIS) would be worth
$3,102.41
+$2,102.41 (+210.2%) today · 3.10× · US Dollar
Based on a CRIS entry price of $1.66 vs. today's $5.15.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4.89 | $1,053.17 | +5.3% |
| 1 month ago | $0.42 | $12,261.91 | +1126.2% |
| 3 months ago | $0.59 | $8,728.81 | +772.9% |
| 6 months ago | $0.87 | $5,919.54 | +492.0% |
| 1 year ago | $1.66 | $3,102.41 | +210.2% |
| All time (5.0y) ago | $145 | $35.52 | -96.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CRIS forecast.
Our base-case forecast reaches $10.00 around 2050.
Implied market cap at $10.00: $19.49M
Looking across the multi-year forecast, Curis, Inc. shows a bullish tilt beginning in 2030 and continuing through 2031 and toward 2050. The 2030 average is $6.69 with ROI 41.4 and sentiment BULLISH, followed by 2031 with an average of $6.58 and ROI 39.1 (BULLISH).
The longer horizon includes 2035 with average $6.48 and ROI 37, and 2040 with average $5.91 and ROI 25 (both NEUTRAL/BULLISH signals depending on year).
In 2032 the average is $5.66 (ROI 19.6), 2033 $5.60 (ROI 18.3), and 2034 $5.40 (ROI 14.2). The 2029 forecast shows average $5.40 (ROI 14.3). The far horizon reaches 2050 with an average of $16.38 and ROI 246.3 (BULLISH).
These figures imply meaningful upside over the longer term, but they also include years with lower or negative ROIs (e.g., 2027 ROI -9.5 and 2028 ROI -11.6). Investors should consider the mix of neutral and bullish years and recognize that these are estimates, not guarantees.
Tap a question to reveal the answer.
2030: avg $6.69, min $4.14, max $11.60; ROI 41.4; sentiment BULLISH.
Near-term 2026 shows avg $4.73 with ROI 0 and sentiment NEUTRAL. Longer term, 2030 (avg $6.69, ROI 41.4) and 2050 (avg $16.38, ROI 246.3) show bullish potential, but 2027 and 2028 have negative ROIs (-9.5 and -11.6). These are estimates, not guarantees.
Yes, forecast max values include $11.60 in 2030, $11.82 in 2031, $12.94 in 2035, and $12.97 in 2040, indicating possible upside beyond $12 in the horizon.
Current price is $4.73 and market cap is $9.22M. The rank is 5156.
Near-term bearish sentiment is indicated, with a 30-day range of $2.72–$8.22 and annualized volatility of 200%. The forecast includes years with negative ROIs (e.g., 2027 -9.5, 2028 -11.6) alongside bullish years (e.g., 2030 41.4, 2050 246.3). These are estimates, not guarantees.
Curis, Inc. Community Discussion
0Share your Curis, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.